drugset / Trial / NCT00437268

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

NCT00437268

Phase 2 Completed 26 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

To see how well enzastaurin in combination with irinotecan and cetuximab works versus irinotecan and cetuximab in participants who have progressed within 3 months.

Timeline

Start
2007-03
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 500 mg Oral
Background Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Background Irinotecan Small molecule 300 mg/m2 Intravenous

Indications